Clal Biotechnology | CBI - Operating Profit


Clal Biotechnology reported ILS-1.74M in Operating Profit for its fiscal quarter ending in December of 2022.





Operating Profit Change Date
Arca Biopharma USD -36.43M 2M Mar/2026
aTyr Pharma USD -128K 24.6M Mar/2026
Bio Path USD -297K 191K Mar/2026
Brainstorm Cell Therapeutics USD -2.05M 198K Mar/2026
Cara Therapeutics USD -7.05M 1.11M Mar/2026
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD -9.02M 65.06M Mar/2026
Immunic USD -23.33M 2.67M Dec/2025
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
RedHill Biopharma USD -4.22M 1.8M Jun/2024
TherapeuticsMD USD -1.18M 40K Jun/2024